Details of the Drug

General Information of Drug (ID: DM9Y6X7)

Drug Name
Clodronate
Synonyms
Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)
Indication
Disease Entry ICD 11 Status REF
Hypercalcaemia 5B91.0 Approved [1]
Therapeutic Class
Antihypocalcemic Agents
Affected Organisms
Humans and other mammals
ATC Code
M05BA02: Clodronate
M05BA: Bisphosphonates
M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05: DRUGS FOR TREATMENT OF BONE DISEASES
M: MUSCULO-SKELETAL SYSTEM
M05BA02: Clodronate
M05BA: Bisphosphonates
M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05: DRUGS FOR TREATMENT OF BONE DISEASES
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 244.89
Logarithm of the Partition Coefficient (xlogp) -2.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 44.2 mgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 16.1 mg/L [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 1-2% [2]
Clearance
The renal clearance of drug is 90 mL/min [4]
Elimination
80% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.6 hours [4]
Metabolism
The drug is not metabolised [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.64% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.88 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.395 mg/mL [3]
Chemical Identifiers
Formula
CH4Cl2O6P2
IUPAC Name
[dichloro(phosphono)methyl]phosphonic acid
Canonical SMILES
C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
InChI
InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
InChIKey
ACSIXWWBWUQEHA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
25419
ChEBI ID
CHEBI:110423
CAS Number
10596-23-3
UNII
0813BZ6866
DrugBank ID
DB00720
TTD ID
D00HNB
VARIDT ID
DR00994

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenine nucleotide translocator 1 (SLC25A4) TTU5A6Q ADT1_HUMAN Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(E3-independent) E2 ubiquitin-conjugating enzyme OTHGS2VA UBE2O_HUMAN Gene/Protein Processing [7]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [7]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [7]
3'-5' RNA helicase YTHDC2 OTYDYKDY YTDC2_HUMAN Gene/Protein Processing [7]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Gene/Protein Processing [7]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Gene/Protein Processing [7]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) OTQYEXL2 F264_HUMAN Gene/Protein Processing [7]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Gene/Protein Processing [7]
ADP-ribosylation factor-like protein 1 (ARL1) OTB6N6BR ARL1_HUMAN Gene/Protein Processing [7]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
2 Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009;29(6):359-79. doi: 10.2165/00044011-200929060-00001.
3 BDDCS applied to over 900 drugs
4 Health Canada Approved Drug Products: Clodronate Oral Capsules
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.
7 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.